NO20042958L - Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus - Google Patents

Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus

Info

Publication number
NO20042958L
NO20042958L NO20042958A NO20042958A NO20042958L NO 20042958 L NO20042958 L NO 20042958L NO 20042958 A NO20042958 A NO 20042958A NO 20042958 A NO20042958 A NO 20042958A NO 20042958 L NO20042958 L NO 20042958L
Authority
NO
Norway
Prior art keywords
poxviruses
methods
containing poxviruses
stable compositions
preparing stable
Prior art date
Application number
NO20042958A
Other languages
English (en)
Norwegian (no)
Inventor
Karl Heller
Ingmar Rathe
Paul Howley
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042958(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20042958L publication Critical patent/NO20042958L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20042958A 2001-12-10 2004-07-09 Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus NO20042958L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10
PCT/EP2002/013434 WO2003053463A2 (en) 2001-12-10 2002-11-28 Poxvirus-containing compositions and process for their preparation

Publications (1)

Publication Number Publication Date
NO20042958L true NO20042958L (no) 2004-07-09

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042958A NO20042958L (no) 2001-12-10 2004-07-09 Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus

Country Status (22)

Country Link
US (1) US7094412B2 (pt)
EP (1) EP1418942B1 (pt)
JP (1) JP4439263B2 (pt)
KR (1) KR20040074067A (pt)
CN (1) CN1296096C (pt)
AT (1) ATE300954T1 (pt)
AU (1) AU2002361962A1 (pt)
BR (1) BR0214822A (pt)
CA (1) CA2467365C (pt)
DE (1) DE60205388T2 (pt)
DK (1) DK1418942T3 (pt)
EA (1) EA006880B1 (pt)
ES (1) ES2247414T3 (pt)
HK (1) HK1071295A1 (pt)
HU (1) HUP0402179A3 (pt)
IL (2) IL161590A0 (pt)
MX (1) MXPA04005577A (pt)
NO (1) NO20042958L (pt)
NZ (1) NZ533302A (pt)
PL (1) PL213326B1 (pt)
UA (1) UA78738C2 (pt)
WO (1) WO2003053463A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PT1434858E (pt) 2002-09-05 2008-07-28 Bavarian Nordic As Método de amplificação de um poxvírus em condições sem soro
CN1207005C (zh) * 2002-10-31 2005-06-22 威世药业(如皋)有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
CN101360821A (zh) * 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
BRPI0811161A2 (pt) * 2007-05-18 2014-10-07 Medimmune Llc Conservação de materiais bioativos por espuma liofilizada.
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 hiv에 대한 광범위한 t-세포 반응의 생성
KR20130008645A (ko) 2010-05-21 2013-01-22 에이에이치 유에스에이 42 엘엘씨 광견병 바이러스 항원을 함유하는 파라폭스바이러스 벡터
JP2013537409A (ja) 2010-07-20 2013-10-03 ゾエティス・エルエルシー パラポックスウイルスベクター
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
BR112015000530A2 (pt) 2012-07-10 2018-08-28 Transgene Sa vacina de antígeno micobacteriano.
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
EP3116541B1 (en) 2014-03-12 2019-11-27 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
KR102658198B1 (ko) * 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
JP7272965B2 (ja) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Hiv抗原をコードするポックスウイルスベクターおよびその使用方法
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
BR112020018117A2 (pt) 2018-03-07 2020-12-22 Transgene Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
US20210386807A1 (en) 2018-10-30 2021-12-16 The University Of Tokyo Oncolytic virus for cancer therapy
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
CN115243717A (zh) 2020-03-12 2022-10-25 巴法里安诺迪克有限公司 改善痘病毒稳定性的组合物
US12029787B2 (en) 2020-07-01 2024-07-09 University Of Connecticut Method for generating recombinant poxviruses
CA3189238A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024188801A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production
WO2024188803A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Production of poxviruses from quail cell cultures
WO2024188802A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (pt)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (pt) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
CA2158935A1 (en) 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
MY150893A (en) * 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
DE60205388T2 (de) 2006-03-30
KR20040074067A (ko) 2004-08-21
AU2002361962A1 (en) 2003-07-09
WO2003053463A2 (en) 2003-07-03
UA78738C2 (en) 2007-04-25
US7094412B2 (en) 2006-08-22
BR0214822A (pt) 2004-12-14
HK1071295A1 (en) 2005-07-15
EA006880B1 (ru) 2006-04-28
WO2003053463A3 (en) 2004-03-04
CN1602205A (zh) 2005-03-30
CN1296096C (zh) 2007-01-24
EA200400796A1 (ru) 2004-12-30
EP1418942A2 (en) 2004-05-19
IL161590A0 (en) 2004-09-27
ES2247414T3 (es) 2006-03-01
CA2467365A1 (en) 2003-07-03
JP4439263B2 (ja) 2010-03-24
DK1418942T3 (da) 2005-11-28
CA2467365C (en) 2012-11-20
JP2005513109A (ja) 2005-05-12
HUP0402179A3 (en) 2012-09-28
IL161590A (en) 2009-06-15
MXPA04005577A (es) 2005-04-19
PL369954A1 (en) 2005-05-02
PL213326B1 (pl) 2013-02-28
US20050019349A1 (en) 2005-01-27
DE60205388D1 (de) 2005-09-08
NZ533302A (en) 2005-11-25
EP1418942B1 (en) 2005-08-03
HUP0402179A2 (hu) 2005-01-28
ATE300954T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
NO20042958L (no) Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus
AU2002231544A1 (en) Therapeutic uses of herbal compositions
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
GB0119011D0 (en) Treatment of nail infections
NZ596367A (en) Lyophilized therapeutic peptibody formulations
BRPI0511441B8 (pt) composições contendo uma partícula de glucano oca ou partícula de parede celular encapsulando um componente de terpeno, métodos de fabricação e uso das mesmas
AR030088A1 (es) Nueva composicion de minoxidilo
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
GEP20053497B (en) Compositions for Enhanced Acaricidal Activity
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
EP4085131A4 (en) AGAINST THE SARS-CORONAVIRUS 2 IMMUNOGENE COMPOSITIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO2002087494A3 (en) Novel vaccine
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
ITMI20031640A1 (it) Base per gel bioadesivi.
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
AU2001256384A1 (en) Cosmetic or dermatological cream composition, the preparation and the use thereof
CN105326762A (zh) 一种芦荟保湿护手霜
BRPI0103733A8 (pt) Método de encapsulação de ingredientes alimentícios e composição alimentícia
PT1363603E (pt) Processo para tornar hidrossoluvel um anti-septico pouco soluvel em agua

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application